HEMATOLOGICAL PARAMETERS OF CHRONIC MYELOID LEUKEMIA PATIENTS IN SUDAN TREATED WITH IMATINIB
Noah Awad*, Aboalgasim Abaas, Nawal Altayeb and Hiba Khalil
ABSTRACT
Background and Objectives: Chronic myeloid leukemia (CML) is disease that differentiated by gene called the bcr-abl fusion gene which produced bcr-abl fusion protein. The detection of tyrosine kinase inhibitor (TKI), imatinib, enhancement the treatment of CML patients. Our general objective is to determine the Hematological parameters in Sudanese patients with chronic myeloid leukemia treated with Imatinib, the specific objectives to correlate the hematological parameters with phases. Methods: Descriptive study conducted from June 2017 to October 2019 at Alneelain University, faculty of Medical Laboratory Sciences, Khartoum, Sudan. All CML patients were diagnosed Positive of Philadelphia chromosome from Hematology oncology at Radio and Isotope Center at Khartoum, Sudan after the approval of study. Patients were included sexes, Philadelphia chromosome result, bone marrow report, clinical feature, WHO criteria for phases of disease and treatment. Results: The numbers of male patients were 67 (67%), while the numbers of females were 33 (33%) as can be seen in Fig.1. Ages of the studied patients ranged from 10 to 70 years. The mean ages of the population were 43.89 years. The mean ages of males were 46.22years; and that of females were 41.75 years. The ratio of male to female is 2:1. Interpretation & conclusions: It can be concluded that treatment of CML patients with Imatinib mesylate caused complete WBCs decrease to normal range. The major hematologic and cytogenetic response was noticed when using a higher dose of Imatinib mesylate.
Keywords: Chronic Myeloid Leukemia, Imatinib, Myeloproliferative disease.
[Full Text Article]
[Download Certificate]
Impact Factor : 8.181 
